Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation

Anticoagulation is recommended for hypertrophic cardiomyopathy (HCM) with nonvalvular atrial fibrillation (NVAF) according to European and American guidelines. However, it is unclear whether HCM is a risk factor for thromboembolism in NVAF in Japan, and the management for NVAF with HCM is not established.

Source: Heart Rhythm - November 29, 2018 Category: Cardiology Authors: Toyonobu Tsuda, Kenshi Hayashi, Noboru Fujino, Tetsuo Konno, Hayato Tada, Akihiro Nomura, Yoshihiro Tanaka, Kenji Sakata, Hiroshi Furusho, Masayuki Takamura, Masa-aki Kawashiri, Masakazu Yamagishi, the Hokuriku-Plus AF Registry Investigators Source Type: research